Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Alice Morigi"'
Autor:
Beatrice Casadei, Lisa Argnani, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Vittorio Stefoni, Paolo E. Coppola, Matteo Carella, Michele Cavo, Pier Luigi Zinzani
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7830-7836 (2020)
Abstract Programmed death‐1 (PD1) blockade is an efficient and safe therapeutic option in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, a substantial proportion of patients’ progresses or loses the response to
Externí odkaz:
https://doaj.org/article/59e93f11c511493180f4ed9f296c34cc
Autor:
Alessandro Broccoli, Lisa Argnani, Alice Morigi, Laura Nanni, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 24, p 5845 (2021)
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refractory chronic lymphocytic leukemia (CLL), even in cases with unfavorable cytogenetics and molecular markers. All CLL patients’ data treated at our I
Externí odkaz:
https://doaj.org/article/54d842930292496791cf11bb83061aee
Autor:
Beatrice Casadei, Alessandro Broccoli, Vittorio Stefoni, Cinzia Pellegrini, Miriam Marangon, Alice Morigi, Laura Nanni, Ginevra Lolli, Matteo Carella, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
Externí odkaz:
https://doaj.org/article/7ba1ac885aea4513b53503f182ef2591
Autor:
Beatrice Casadei, Lisa Argnani, Serafina Guadagnuolo, Cinzia Pellegrini, Vittorio Stefoni, Alessandro Broccoli, Laura Nanni, Alice Morigi, Ginevra Lolli, Maria Guarino, Luca Spinardi, Elisabetta Pierucci, Stefano Fanti, Michele Bartoletti, Michele Dicataldo, Elena Sabattini, Francesca Bonifazi, Pier Luigi Zinzani
Publikováno v:
Cancers, Vol 13, Iss 19, p 4789 (2021)
Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma. Although outcomes have improved thanks to the introduction of rituximab-based chemoimmunotherapy, certain LBCL still represents a challenge because of initial resistance
Externí odkaz:
https://doaj.org/article/4bc6eb7d30c446dbbbd35f6aaa8fa6c6
Autor:
Alessandro Broccoli, Beatrice Casadei, Vittorio Stefoni, Cinzia Pellegrini, Federica Quirini, Lorenzo Tonialini, Alice Morigi, Miriam Marangon, Lisa Argnani, Pier Luigi Zinzani
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least two decade
Externí odkaz:
https://doaj.org/article/57025dcd6c6441119dc1a81a2b6a4fa4
Autor:
Laura Nanni, Gerardo Musuraca, Alice Morigi, Vittorio Stefoni, Monica Barone, Gabriele Conti, Marco Fabbrini, Silvia Turroni, Alessandro Broccoli, Lisa Argnani, Patrizia Brigidi, Pier Luigi Zinzani
Publikováno v:
Blood. 140:4961-4963
Autor:
Alessandro Broccoli, Lisa Argnani, Laura Nanni, Gianmarco Bagnato, Matteo Carella, Beatrice Casadei, Paolo Elia Coppola, Gabriele Gugliotta, Ginevra Lolli, Marianna Gentilini, Alice Morigi, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Publikováno v:
Blood. 140:6526-6527
Autor:
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani
Publikováno v:
Journal of cancer research and clinical oncology.
Purpose One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT). Finding a salvage reg
Autor:
Alessandro Broccoli, Lisa Argnani, Paolo Elia Coppola, Marianna Gentilini, Gianmarco Bagnato, Ginevra Lolli, Matteo Carella, Laura Nanni, Alice Morigi, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
The follow-up of the pivotal trial and large case series reports of a proportion of patients, between 5% and 9%, with relapsed or refractory Hodgkin lymphoma failing autologous stem cell transplantation and treated with brentuximab vedotin, achieving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90577faf1568d29decfb39b1bdfdc6de
http://hdl.handle.net/11585/882767
http://hdl.handle.net/11585/882767
Autor:
Carolina Terragna, Pier Luigi Zinzani, Alessandro Broccoli, Marina Martello, Cinzia Pellegrini, Silvia Armuzzi, Elena Sabattini, Claudio Agostinelli, Alice Morigi, Laura Nanni, Vittorio Stefoni, Lisa Argnani, Beatrice Casadei
BRAFV600E mutation is the pathogenic driver of hairy cell leukemia (HCL) found in the vast majority of cases both at onset and during recurrences. The identification of the mutated allele in blood and marrow correlates with the presence of neoplastic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cfc58020ab1683193a7308eaba6f762
http://hdl.handle.net/11585/882089
http://hdl.handle.net/11585/882089